India Pharmacopoeia Commission joins WHO network

Published: 10-Dec-2015
Regulatory

India has set up 179 centres to monitor adverse drug reactions across the country


The Indian Pharmacopoeia Commission (IPC) is set to become the first World Health Organisation (WHO) Collaborating Centre for the safety of medicines and vaccines in the south and south-east Asia region. These bodies work with the WHO to develop and implement policy.

The move has been welcomed by Indian health and Welfare Minister Shri J P Nadda, who stressed the need to improve pharmacovigilance in the region as 'an effective instrument for understanding and prevention of adverse effects or any other drug related problems'.

He noted that India has set up 179 centres to monitor adverse drug reactions across the country.

  • Companies:
  • World Health Organization
See more

You may also like

Personal Protection

Containment: key to tackling coronavirus outbreak

Read more
China and WHO authorities agreed that further studies on the severity and transmissibility of the virus are needed and immediate communication of any findings is crucial

Trending Articles

  1. Navigating regulatory challenges in pharmaceutical packaging: lessons from the past and strategies for the future To safeguard drug efficacy, maintain strict quality standards and ensure patient safety, pharmaceutical packaging is subject to a wide range of regulations around the world, reports Kun Shing Chan, Director of QA at Tjoapack
  2. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  3. Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia
  4. AbbVie's Elahere approved for platinum-resistant ovarian cancer by the European Commission Elahere is the first FRα-targeting antibody-drug conjugate (ADC) to be approved in Europe for platinum-resistant ovarian cancer
  5. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Personal Protection

Containment: key to tackling coronavirus outbreak

China and WHO authorities agreed that further studies on the severity and transmissibility of the virus are needed and immediate communication of any findings is crucial
Regulatory

WHO proposes central registry on human genome editing research

On the heels of the Chinese CRISPR scandal, stakeholders in the genome editing industry will be consulted to create standards for future research
Regulatory

Annex 1 harmonisation moves a step closer

Revision to Annex 1 on the manufacturing of sterile medicinal products of the PIC/S – EU GMP Guide goes out for joint stakeholder consultation
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

EU considers endocrine disrupter controls

It has long been known that pharmaceutical residues can become hormone-affecting ‘endocrine disrupters’ when released into the environment and future controls are likely – but how will the legislators tackle the issue? Manufacturing Chemist reports
Regulatory

European Commission, EMA and WHO step up co-operation to protect global public health

New working arrangement will allow timely sharing of non-public information
Regulatory

Vietnamese national regulatory authority meets international standards for vaccine regulation

The World Health Organisation has formally certified that Vietnam has a fully equipped national regulatory system that ensures the safety and efficacy of vaccines produced and used in the country
Regulatory

Chinese medicine body joins list of WHO observers

Will give traditional Chinese medicine (TCM) a voice in international health affairs
Subscribe now